Market open

Zomedica/$ZOM

14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX

About Zomedica

Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.

Ticker

$ZOM
Sector
Health Care

Trading on

AMEX

Industry

Health Care Equipment & Supplies
Headquarters
Ann Arbor, United States

Employees

144
Website
www.zomedica.com

Zomedica Metrics

BasicAdvanced
$124M
-
-$0.06
1.06
-

$124M

1.06

$0.20

$0.12

7.1M

10.822

9.829

0.712

1.024

-9.78%

-26.82%

4.646

0.61

1.17

-4.018

11.33%

316.53%

701.03%

0.26%

What the Analysts think about Zomedica

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Zomedica stock.

Zomedica Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zomedica Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Zomedica News

AllArticlesVideos
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market

Accesswire·1 week ago
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone

Accesswire·3 weeks ago
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZOM

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Zomedica stock?

Zomedica (ZOM) has a market cap of $124M as of January 15, 2025.

What is the P/E ratio for Zomedica stock?

The price to earnings (P/E) ratio for Zomedica (ZOM) stock is 0 as of January 15, 2025.

Does Zomedica stock pay dividends?

No, Zomedica (ZOM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Zomedica dividend payment date?

Zomedica (ZOM) stock does not pay dividends to its shareholders.

What is the beta indicator for Zomedica?

Zomedica (ZOM) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.